热门资讯> 正文

Emergent BioSolutions签署价值3450万美元的疫苗制造和分销协议

2026-04-28 20:42

Emergent BioSolutions Inc.(EBS) 0

Emergent BioSolutions (EBS) entered a ~$34.5M agreement with Substipharm Biologics for JE vaccine manufacturing and distribution.
The deal covers drug substance production for the IMOJEV Japanese Encephalitis vaccine.
Emergent will be the exclusive distributor to the U.S. government pending FDA approval.
Manufacturing will take place at its Canton, Massachusetts facility.
Emergent is scaling up production and plans to hire additional staff.
The agreement supports regulatory submission efforts for U.S. approval of the vaccine.

More on Emergent Biosolutions

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation
Emergent BioSolutions secures $60M contracts
Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。